ENT4 Antibody

What is ENT4 and why is it important to study with antibody-based techniques?

ENT4 is a 530 amino acid plasma membrane protein with 10-12 transmembrane segments that functions as an equilibrative nucleoside transporter . This protein carries significant importance as it catalyzes the reuptake of monoamines into presynaptic neurons, thus determining the intensity and duration of monoamine neural signaling . Recent research has established ENT4 as a pH-dependent adenosine transporter that also accepts biogenic amines as substrates, earning it the alternative name of plasma membrane monoamine transporter (PMAT) .

ENT4 has been localized to several critical regions: endothelial cells in the blood-brain barrier, the luminal membrane of choroid epithelial cells, and neurons . Its expression profile and transport functions make it relevant to neuroscience research, particularly in studying monoaminergic signaling pathways. Furthermore, ENT4 has been identified as a direct target of EWS/WT1 transcription factor and is highly expressed in desmoplastic small round cell tumors (DSRCT), suggesting its significance in oncology research .

For these research areas, antibody-based detection of ENT4 is essential for studying its expression, localization, and functional interactions in both normal and pathological states.

What are the critical considerations for ENT4 antibody validation?

Validation of ENT4 antibodies requires multiple complementary approaches to ensure specificity and reliability across experimental applications. The following methodological considerations are essential:

• Epitope verification: Confirm that the antibody recognizes the intended epitope of ENT4. For example, commercially available antibodies like the one from Synaptic Systems (Cat. No. 463 005) target a synthetic peptide corresponding to amino acids 505-528 from mouse ENT4 .

• Species reactivity testing: Document cross-reactivity with ENT4 from different species. The aforementioned antibody reacts with mouse (Q8R139) and rat (F1M2Y4) ENT4 .

• Application-specific validation: Antibody performance must be validated separately for each application (western blot, immunohistochemistry, flow cytometry, etc.) as the experimental context significantly affects antibody-antigen interactions .

• Negative controls: Include samples where ENT4 is known to be absent or knocked down to confirm antibody specificity.

• Positive controls: Use tissues with established ENT4 expression (brain and heart samples) as positive controls .

• Selectivity assessment: Demonstrate the ability of the antibody to differentiate between ENT4 and other closely related nucleoside transporters of the same family .

• Concentration optimization: Determine the optimal working concentration (preferably in μg/ml rather than dilution) for each application to minimize background and maximize specific signal .

What is the recommended handling protocol for ENT4 antibodies?

Based on available information for commercial ENT4 antibodies, the following handling protocols are recommended:

Storage and Reconstitution:

• Store lyophilized antibody at +4°C until use

• For reconstitution, add 50 μl H₂O to get a 1mg/ml solution in PBS

• After reconstitution, aliquot and store at -20°C to -80°C

• Avoid repeated freeze-thaw cycles

• Do not freeze when lyophilized

Documentation in Methods Sections:
When using ENT4 antibodies in research publications, include the following details:

• Species (e.g., rabbit, mouse)

• Clonality (monoclonal/polyclonal)

• Clone name if using a monoclonal antibody

• Concentration used (in μg/ml when possible)

• Commercial source or collaborator details

• References for previous validation

• Epitope details if relevant to interpretation

Application-specific considerations:

• For immunohistochemistry (IHC): Sample preparation methods, especially fixation protocols, can significantly affect epitope accessibility for ENT4 due to its multiple transmembrane domains

• For western blotting: Denaturation conditions may affect epitope recognition, particularly when targeting conformational epitopes within the transporter structure

How should ENT4 expression be properly documented across different tissue types?

When documenting ENT4 expression across tissue types, researchers should implement the following methodological approaches:

• Quantitative comparison: Use quantitative RT-PCR to measure ENT4 transcript levels across tissues. Previous studies have shown differential expression with particularly high levels in certain brain regions, heart tissue, and markedly elevated expression in DSRCT samples compared to Ewing's sarcoma and normal tissues .

• RNA in-situ hybridization: This technique can provide spatial information about ENT4 expression at the transcript level. Previous studies demonstrated tumor-specific ENT4 expression using antisense probes, with no staining observed with control (sense) probes .

• Immunohistochemical analysis: When performing IHC to detect ENT4 across tissues, include:

  • Appropriate positive and negative controls

  • Validation of antibody specificity in each tissue type

  • Assessment of subcellular localization (membrane vs. cytoplasmic)

  • Documentation of staining intensity using standardized scoring systems

• Cross-validation: Confirm protein expression using at least two independent antibodies or methods (e.g., western blot plus IHC) to increase confidence in expression data.

• Expression table: Document ENT4 expression across tissues in a standardized format, including relative expression levels, subcellular localization, and methods used for detection.

How can researchers optimize dual-recognition antibody assays for enhanced ENT4 detection specificity?

Dual-recognition antibody assays, such as sandwich ELISA or proximity ligation assays, can significantly enhance the specificity of ENT4 detection. The principle is to use two antibodies targeting different epitopes of ENT4, which creates a much more stringent detection requirement and reduces false positives .

Methodological considerations for optimizing dual-recognition ENT4 assays:

• Epitope selection: Choose antibodies targeting non-overlapping epitopes of ENT4. For example, pair an antibody targeting the N-terminal region with one targeting the C-terminal region (e.g., AA 505-528 as in the Synaptic Systems antibody) .

• Antibody pairing strategy:

  • For capture: Consider using a less specific polyclonal antibody with broader epitope recognition

  • For detection: Employ a highly specific monoclonal antibody

• Validation experiments:

  • Test each antibody individually to confirm ENT4 recognition

  • Verify that the paired antibodies do not interfere with each other's binding

  • Include negative controls lacking ENT4 expression

  • Use positive controls with known ENT4 expression levels

• Assay optimization:

  • Determine optimal antibody concentrations for both capture and detection

  • Optimize incubation times and washing conditions

  • Establish signal-to-noise ratios at various ENT4 concentrations

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other members of the nucleoside transporter family, particularly those with high sequence homology to ENT4.

This approach is particularly valuable when studying ENT4 in complex biological samples where selectivity challenges exist. The enhanced specificity of dual-recognition approaches can help distinguish ENT4 from closely related transporters and provide more reliable detection in research applications.

What are the methodological approaches for studying the pH-dependence of ENT4 using antibody-based techniques?

ENT4 functions as a pH-dependent adenosine transporter , making pH considerations crucial when studying this protein with antibody-based techniques. Here are methodological approaches for investigating this characteristic:

• pH-controlled immunocytochemistry:

  • Culture cells expressing ENT4 in media buffered at different pH values (pH 6.0-7.4)

  • Fix cells under pH-controlled conditions

  • Perform immunocytochemistry with ENT4 antibodies

  • Analyze changes in subcellular localization or expression level in response to pH

• Functional antibody blocking studies:

  • Pre-treat cells with ENT4 antibodies targeting extracellular domains

  • Measure adenosine uptake at various pH values (e.g., pH 6.0, 6.5, 7.0, 7.4)

  • Compare transport activity to determine if antibody binding affects pH sensitivity

• Conformation-specific antibody development:

  • Generate antibodies that specifically recognize pH-dependent conformational states of ENT4

  • Validate these antibodies under different pH conditions

  • Use them to track conformational changes associated with transport activity

• Combined electrophysiology and immunofluorescence:

  • Perform patch-clamp recordings under different pH conditions

  • Follow with immunostaining to correlate functional changes with protein localization

• Subcellular fractionation with pH adjustment:

  • Fractionate cells under different pH conditions

  • Use ENT4 antibodies for western blot analysis of each fraction

  • Determine if pH affects membrane vs. cytoplasmic distribution

When studying the cytotoxic effects of adenosine analogs that depend on ENT4 transport, researchers should perform experiments across a pH range. Previous research has demonstrated that treatment of DSRCT cells with adenosine analogs such as 2-chloro-2′-deoxyadenosine (2-CdA) resulted in cytotoxic responses that varied in a pH-dependent manner .

How can ENT4 antibodies be effectively used to investigate the role of ENT4 in DSRCT and other tumor models?

ENT4 has been identified as a direct target of the EWS/WT1 transcription factor and is highly expressed in desmoplastic small round cell tumors (DSRCT) . The following methodological approaches can effectively utilize ENT4 antibodies in tumor research:

• Expression profiling in tumor samples:

  • Perform immunohistochemistry on tumor microarrays containing DSRCT, Ewing's sarcoma, and control tissues

  • Quantify expression levels using standardized scoring systems

  • Previous studies have shown that ENT4 expression in DSRCT samples was 2-20 fold higher than in Ewing's sarcoma samples

• Correlation with EWS/WT1 expression:

  • Co-stain tumor samples for both ENT4 and EWS/WT1

  • Perform co-immunoprecipitation to investigate physical interactions

  • Use chromatin immunoprecipitation (ChIP) to confirm direct regulation of ENT4 by EWS/WT1, as previously demonstrated

• Functional studies in tumor models:

  • Use ENT4 antibodies for immunoprecipitation followed by activity assays

  • Develop blocking antibodies to inhibit ENT4 function in tumor cells

  • Combine with adenosine analog treatment to assess therapeutic potential

• Diagnostic applications:

  • Evaluate ENT4 immunostaining as a diagnostic marker for DSRCT

  • Compare sensitivity and specificity with current diagnostic standards

  • Develop dual-staining protocols combining ENT4 with other DSRCT markers

• Therapeutic target validation:

  • Use ENT4 antibodies to monitor expression changes following experimental therapies

  • Develop antibody-drug conjugates targeting ENT4 in tumor cells

  • Perform biodistribution studies with labeled ENT4 antibodies

Research has shown that DSRCT cells are sensitive to adenosine analogs in a manner dependent on ENT4 expression and function . This suggests that ENT4 may represent not only a diagnostic marker but also a potential therapeutic target in DSRCT, which antibody-based approaches could help to validate and exploit.

What challenges exist in distinguishing ENT4 from other nucleoside transporters, and how can antibody design address these?

Distinguishing ENT4 from other members of the nucleoside transporter family presents significant challenges due to sequence homology and similar structural features. Advanced antibody design approaches can help address these challenges:

• Epitope selection strategies:

  • Target unique regions with minimal sequence conservation across the transporter family

  • The C-terminal region (AA 505-528) used in some commercial antibodies offers higher specificity

  • Avoid epitopes in the transmembrane domains which have higher conservation

• Computational antibody design:

  • Apply biophysics-informed models to predict antibody-epitope interactions

  • Generate antibodies with customized specificity profiles that can discriminate between closely related epitopes

  • Use high-throughput sequencing and computational analysis to select optimal binding sequences

• Experimental validation approaches:

  • Express individual nucleoside transporters in cell lines lacking endogenous expression

  • Test antibody cross-reactivity systematically against each family member

  • Perform competition assays with purified transporter proteins or peptides

• Application-specific optimization:

  • For western blotting: Use SDS-PAGE conditions that maximize size differences between transporters

  • For immunohistochemistry: Optimize antigen retrieval methods specific to ENT4 epitopes

  • For flow cytometry: Develop multi-parameter approaches with transporter-specific markers

• Machine learning-assisted epitope mapping:

  • Apply machine learning algorithms to identify epitopes that maximize specificity

  • Train models on experimental data from phage display selections against multiple related transporters

  • Generate antibody variants with optimal binding properties

Recent advances in computational antibody design have shown promise in developing antibodies with highly specific binding properties, even for closely related targets. These approaches can identify different binding modes associated with specific ligands and generate antibody variants not present in initial libraries that exhibit customized specificity profiles .

What are the best practices for using ENT4 antibodies in blood-brain barrier (BBB) research?

ENT4 has been localized to endothelial cells in the blood-brain barrier , making it relevant for BBB research. The following best practices should be implemented when using ENT4 antibodies in this context:

• Model system selection:

  • Primary brain endothelial cells vs. immortalized cell lines

  • In vivo models with intact BBB

  • Organoid or microfluidic BBB models

• Immunolocalization in BBB models:

  • Use confocal microscopy to determine precise localization (luminal vs. abluminal)

  • Co-stain with established BBB markers (e.g., tight junction proteins, transporters)

  • Perform z-stack analysis to confirm membrane vs. cytoplasmic localization

• Functional correlation studies:

  • Correlate ENT4 expression with barrier properties (TEER, permeability)

  • Investigate the impact of ENT4 blockade on adenosine transport across BBB models

  • Study pH-dependent transport functions relevant to pathological conditions

• Pathological state assessment:

  • Compare ENT4 expression and localization in healthy vs. diseased BBB models

  • Study regulation of ENT4 under inflammatory conditions or in response to CNS diseases

  • Assess potential as a therapeutic target for CNS drug delivery

• 3D reconstruction techniques:

  • Apply super-resolution microscopy with ENT4 antibodies

  • Perform 3D reconstruction of BBB models to map ENT4 distribution

  • Quantify expression densities across different BBB regions

In BBB research, particular attention should be paid to fixation and permeabilization protocols, as these can significantly affect the detection of membrane transporters like ENT4. The antibody performance depends critically on the quality of sample preparation, especially when working with complex BBB models .